Saniona AB
STO:SANION
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Saniona AB
Common Stock
Saniona AB
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Saniona AB
STO:SANION
|
Common Stock
kr6.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
21%
|
|
|
Genmab A/S
CSE:GMAB
|
Common Stock
kr10m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Common Stock
kr71.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Common Stock
$1.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Common Stock
€2.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
223%
|
CAGR 10-Years
94%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Common Stock
kr792.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
Saniona AB
Glance View
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
See Also
What is Saniona AB's Common Stock?
Common Stock
6.9m
SEK
Based on the financial report for Dec 31, 2025, Saniona AB's Common Stock amounts to 6.9m SEK.
What is Saniona AB's Common Stock growth rate?
Common Stock CAGR 10Y
21%
Over the last year, the Common Stock growth was 23%. The average annual Common Stock growth rates for Saniona AB have been 30% over the past three years , 17% over the past five years , and 21% over the past ten years .
